Form 4: NeuroPace Director Joseph Lacob Granted 8,745 Stock Options

NeuroPace Inc. Director Joseph Lacob was granted 8,745 stock options with an exercise price of $13.15, vesting monthly over one year.

Summary

• Joseph Lacob, a Director of NeuroPace Inc. (NPCE), was granted 8,745 stock options.
• The options have an exercise price of $13.15 per share.
• The shares subject to the option will vest in twelve equal consecutive monthly installments.
• Full vesting is contingent upon Mr. Lacob's continuous service through each vesting date.
• The transaction date for this grant was June 6, 2025.
• The options have an expiration date of June 5, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management/board and shareholder interests, and a standard practice for incentivizing long-term performance. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule over 12 months encourages continued service and commitment from the director.

Negatives

• The options only become valuable if the stock price rises above the exercise price of $13.15.
• There is potential for future dilution if all options are exercised, although the number of shares is relatively small.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

The granting of stock options to directors is a common practice across various industries, including the medical device and technology sectors where NeuroPace operates, as a form of long-term incentive compensation and to align interests with shareholders.

Comparison to Industry Standards

• The grant of 8,745 stock options to a director is a standard practice for executive and director compensation in publicly traded companies.
• The specific number and exercise price would typically be benchmarked against peer companies in the medical device or neurotechnology sector, considering the company's size, performance, and the director's role. Without specific peer data, a direct comparison is not possible from this document alone.

Corporate Governance

Related Party Transactions

• This document reports a related party transaction, specifically the grant of stock options from NeuroPace Inc. to Joseph Lacob, who is a Director of the company.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: No direct impact on employees is mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The options will vest in twelve equal consecutive monthly installments, subject to continuous service.

Key Dates

Keywords

NeuroPace Inc., NPCE, Joseph Lacob, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting